# 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

> **NCT01183897** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic

## Key facts

- **NCT ID:** NCT01183897
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-12
- **Primary completion:** 2018-09-25
- **Final completion:** 2018-09-25
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01183897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01183897, "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01183897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*